Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Return on Sales (2023 - 2025)

CG Oncology filings provide 3 years of Return on Sales readings, the most recent being 0.18% for Q4 2025.

  • On a quarterly basis, Return on Sales rose 52.0% to 0.18% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.4%, a 37.0% increase, with the full-year FY2025 number at 0.4%, up 37.0% from a year prior.
  • Return on Sales hit 0.18% in Q4 2025 for CG Oncology, up from 0.26% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.18% in Q4 2025 to a low of 165.51% in Q4 2023.
  • Median Return on Sales over the past 3 years was 1.7% (2024), compared with a mean of 17.81%.
  • Biggest five-year swings in Return on Sales: surged 16481bps in 2024 and later tumbled -631bps in 2025.
  • CG Oncology's Return on Sales stood at 165.51% in 2023, then surged by 100bps to 0.7% in 2024, then surged by 75bps to 0.18% in 2025.
  • The last three reported values for Return on Sales were 0.18% (Q4 2025), 0.26% (Q3 2025), and 2.32% (Q2 2025) per Business Quant data.